Louis Garguilo's Articles
-
New Year’s Resolution: Teach Industry About COVID-19 Supply Chain Challenges
1/1/2021
When vaccines have been administered and COVID-19 is at bay, hopefully the vaccine makers and their partners will provide the entire drug development and manufacturing industry with details about the challenges they encountered in their supply chains.
-
Remembering The Year We’d Rather Forget
12/19/2020
We verified through a dismaying pandemic, outsourcing drug development and manufacturing is sustainable. But this annus horribilis also laid bare supply-chain vulnerabilities. Here’s the best and worst of your 2020.
-
Do Your CDMO And Consultants Get Along? They Better
12/15/2020
"As biopharma companies become more virtual, the relationship between your CDMOs and consultants is really key to your success,” says Evelyn Kelly, founder and managing director, Orphan Drug Consulting Ltd.
-
How To Find Your Safe-Harbor Consultant
12/8/2020
Dublin-based Orphan Drug Consulting founder Evelyn Kelly explains how to navigate to the consultants right for you. Hint: It doesn’t include longer term contracts, but may a good dose of advice – free of charge.
-
Meet Your New “Person”-In-Plant: iPad On IV, Ph.D.
12/1/2020
Joseph Graskemper of Translate Bio was recently involved in a process to create a V-PIP [virtual person-in-plant] at his CDMO. Turns out to be something that should carry on post-COVID-19, and prompt readers and your service providers to some ingenuity of your own.
-
Primal Motivations: Stop Drug Shortages, Start Domestic Supply Chains
11/21/2020
“So in the spring of 2019,” recalls Eric Edwards, “I put my doctor’s white coat back on, and shadow Dr. Marshall Summar at Children’s National Hospital for a week ...” Part 3 of my exclusive interview w/ the CEO of Phlow Corporation – the motives, mission, and message.
-
What’s A “Biopharma CDMO”?
11/15/2020
In part two of my exclusive interview with Phlow Corporation's CEO Dr. Eric Edwards, we turn our attention to biopharma business models and CDMO partnerships.
-
You Don’t Know Phlow: The Backstory Of A Misread Biopharma Start-Up
11/9/2020
No biopharma start-up has been as misconstrued, hastily judged in strategy and capability, or even labeled “political.” Now Phlow Corporation’s CEO Eric Edwards sets the record straight in an exclusive interview.
-
Where Have All The “Early Amgens” Gone? To Tech Transfers, Every One
11/1/2020
“My opinion is not theoretical. It reflects having seen it in action at Amgen, from 1986 to 1995, with the launching of Epogen & Neupogen.” Like biopharma’s Nietzsche, Mark Witcher wants us to slay outdated beliefs – “tech transfer” being a prime target.
-
The Witcher Way: Can We “Eliminate” Tech Transfer?
10/18/2020
“You can call me a revolutionary, if you like,” responds Mark Witcher upon my comment he is. His thesis on the elimination of "tech transfer" is detailed, and provocative. But is it practical? Readers will make the ultimate judgment.